Serina Therapeutics Inc.
04/21/2026 | Press release | Distributed by Public on 04/21/2026 15:12
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Chief Technology Officer
On April 20, 2026, Serina Therapeutics (AL), Inc. (the "Serina (AL)"), a wholly owned subsidiary of Serina Therapeutics, Inc. (the "Company"), named Srini Tenjarla, Ph.D., its Chief Technology Officer. Dr. Tenjarla had previously served as Serina (AL)'s Senior Vice President of CMC and Formulation since July 2024. In connection with the promotion, Dr. Tenjarla's annual base salary was increased to $425,000, effective back to March 15, 2026.
Chief Executive Officer Compensation
On April 15, 2026, the Company increased the annual base salary of Steve Ledger, the Company's Chief Executive Officer, to $500,000. The increase in base salary was pursuant to Mr. Ledger's employment agreement upon the satisfaction of certain strategic goals, and is effective as of September 9, 2024, the date of Mr. Ledger's employment agreement. The Company has paid the retroactive portion of the base salary increase in a lump sum in April 2026.
Serina Therapeutics Inc. published this content on April 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 21, 2026 at 21:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]